Alembic Pharmaceuticals receives USFDA clearance for Karakhadi facility
Alembic Pharmaceuticals (BSE: 533573) announced today that it has received an Establishment Inspection Report (EIR) from the USFDA for its API-III manufacturing facility located in Karakhadi, India. The inspection by the USFDA took place between March 17, 2025, and March 21, 2025. The company has informed the National Stock Exchange of India Ltd about this development. This approval signifies the successful completion of the USFDA inspection and allows the company to continue manufacturing and exporting pharmaceutical products from this facility to the United States.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when ALEMBIC PHARMACEUTICALS publishes news
Free account required • Unsubscribe anytime